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We investigated the effects of anidulafungin alone and in combination with amphotericin B against Aspergil-
lus fumigatus. Indifference was the only type of interaction observed in vitro. Anidulafungin at 1 and 5 mg/kg
of body weight/day, amphotericin B at 1 mg/kg/day, and combination therapy prolonged the survival of mice
with invasive aspergillosis. Anidulafungin at 5 mg/kg/day, alone and in combination with amphotericin B,
reduced the kidney fungal burden. Overall, the combination was not superior to the most active single drug.
The high mortality rate of invasive aspergillosis has driven
recent efforts to determine the efficacy of combination therapy
in the treatment and management of those infections (1, 6, 7,
16, 17, 19, 20, 23, 29). Therefore, in this study, the in vitro and
in vivo efficacies of the new echinocandin anidulafungin
(AFG), alone and in combination with amphotericin B
(AMB), against Aspergillus fumigatus were analyzed.
Three clinical strains (F2, F3, and F4) isolated from bron-
choalveolar lavage specimens from patients with hematological
diseases were identified to species level by conventional meth-
ods (24).
AMB was used as a pure powder (Sigma) for in vitro studies
and as a commercial preparation (Fungizone; Bristol-Myers
Squibb) for in vivo studies. Pure powder of AFG (Pfizer) was
dissolved in dimethyl sulfoxide and further diluted in the test
medium or sterile saline solution for in vitro and in vivo stud-
ies, respectively.
MICs and minimum effective concentrations (MECs; the
lowest concentrations that led to the growth of small, rounded,
compact hyphal forms compared to the hyphal growth seen in
the growth control well) were determined in RPMI 1640 me-
dium by the CLSI M38-A2 broth microdilution method
(10, 12).
For both susceptibility and checkerboard assays, the MICs
and MECs were read visually at 24 and 48 h (10, 25). Drug
interactions were classified as synergistic, indifferent, or antag-
onistic based on the fractional inhibitory concentration (FIC)
index (16).
Minimum fungicidal concentration (MFC) was considered
the concentration of antifungal agents, alone or in combina-
tion, that yielded no growth (27).
Metabolic activities of conidia and hyphae were assessed in
RPMI 1640 medium with L-glutamine, without phenol red and
NaHCO3, by XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxyanilide inner salt] assay (Tox-2;
Sigma) (2, 3, 21).
An experimental CD1 mouse (Charles River, Calco, Italy)
model of invasive aspergillosis was used by following previously
reported procedures (4). A total of three separate in vivo
studies were performed by injection of the A. fumigatus F3
isolate. The drug treatments were started 2 h after the infec-
tion. AMB at 0.5 and 1 mg/kg of body weight/day, AFG at 1
and 5 mg/kg/day, and combination doses were administered
intraperitoneally.
In survival studies, the mice were treated daily from day 0 to
day 4 and observed for 10 consecutive days.
Brain and kidney fungal burdens were determined at day 4
postinfection by CFU count and quantitative PCR based on
procedures described by Bowman et al. (5).
Histopathology analysis was performed at day 4 postinfec-
tion (4). The number of fungal microabscesses was evaluated
in 20 consecutive microscopic fields. Each section was classi-
fied based on the number of fungal microabscesses as follows:
absence, 5, 5 to 20, and 20.
The in vitro results were analyzed by either Mann-Whitney
U test or Student’s t test, with a P value of 0.05 considered
significant. Survival and tissue burden studies were analyzed by
log rank and Mann-Whitney U tests, respectively. Due to mul-
tiple comparisons, a P value of 0.016 was considered signif-
icant.
Our in vitro results are shown in Table 1. Overall, AFG
MECs were significantly lower than AMB MICs and indiffer-
ence was the only type of interaction among the two drugs.
MFC values for AFG were all 16 g/ml, while the combi-
nation values were statistically lower than those for AFG
alone, but not for AMB alone.
The studies of metabolic activity either on conidia or on
hyphae are presented in Fig. 1.
AFG, AMB, and the combination regimens showed a dose-
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dependent reduction of metabolic activity against conidia, but
generally the combination was not more effective than the
most active drug alone. Against the hyphae, AMB showed a
decreased activity, while AFG was not active. The combination
was effective, but not more effective than AMB alone.
The in vivo results are shown in Fig. 2. In studies 1 and 2, all
drug regimens prolonged significantly the survival over that of
control animals. In both studies, the groups treated with the
combination regimens did not have significantly increased sur-
vival times with the respect to the AMB- and AFG-treated
groups. In study 3, AFG at 5 mg/kg/day and the combination
regimen, but not AMB at 0.5 mg/kg/day, significantly pro-
longed the survival time with the respect to the control group.
Combination treatment did not extend survival beyond that of
the AFG-treated group.
Kidney and brain burden results are shown in Table 2. Only
AFG at 5 mg/kg/day and the respective combination with AMB
were effective at reducing the CFU or conidial equivalent per
gram of kidney tissues. No treatments were effective at reduc-
ing the brain burdens.
TABLE 1. In vitro susceptibility tests of AFG and AMB, alone and in combination, against three clinical isolates of A. fumigatusa
Isolate Drug(s)
MIC or MEC (g/ml) at 24 h MIC or MEC (g/ml) at 48 h MFC (g/ml) at 48 h
Median Range Median Range Median Range
F2 AFG 0.001 0.001–0.002 0.002 0.002 16 16
AMB 0.5 0.25–0.5 1.0 1.0 1.0 1.0–2.0
AFG  AMBb 0.001/0.03 0.001–0.002/0.03–0.06 0.001/0.06 0.001–0.002/0.03–0.06 0.0002/1.0 0.0002/1.0–2.0
F3 AFG 0.001 0.001–0.002 0.002 0.002 16 16
AMB 0.25 0.25–0.5 1.0 0.5–1.0 1.0 0.5–1.0
AFG  AMBb 0.001/0.03 0.001/0.03 0.002/0.03 0.002–0.03 0.0002/1.0 0.0002/0.5–1.0
F4 AFG 0.002 0.001–0.002 0.002 0.002 16 16
AMB 0.25 0.125–0.5 1.0 1.0–2.0 1.0 0.5–1.0
AFG  AMBb 0.002/0.25 0.001–0.002/0.03–0.25 0.002/0.25 0.001–0.002/0.25 0.0002/1.0 0.0002/0.5–1.0
a Each test was run in triplicate and repeated on two different days.
b The MEC values were reported as end point readings of the checkerboard assays. The interaction between the drugs was classified as “indifferent” in each case
(interactions were defined as synergistic if the FIC index was less than or equal to 0.50, indifferent if the FIC index was greater than 0.50 and less than or equal to 4.0,
and antagonistic if the FIC index was greater than 4.0).
FIG. 1. Percentages of metabolic activity of three clinical isolates of A. fumigatus (F2, F3, and F4) at the stage of nongerminated conidia (A) and
filamentous forms (B) detected by XTT assay. AFG (white bars), AMB (striped bars), and the combination of the two antifungal agents (black
bars) were tested to concentrations of 1/4, 1, and 4 times the respective MICs and MECs. The bars represent the means of percent metabolic
activity in the presence of the drugs with respect to the growth controls. The error bars indicate the standard deviations of the means. Letters a
and b indicate reduced metabolic activity of the combination versus AFG and AMB alone, respectively (P  0.05). Each strain was tested in
triplicate.
4036 SPREGHINI ET AL. ANTIMICROB. AGENTS CHEMOTHER.
Consistent with these data, a decreased number of fungal
microabscesses were observed in kidney tissues, but not in
brain tissues, of mice treated with AFG at 5 mg/kg/day (Fig. 3).
Our AFG MEC values were similar to those previously re-
ported for A. fumigatus isolates (12, 22). In agreement with a
previous study conducted by Philip et al. (28), AFG used in
combination with the polyene yielded an indifferent type of
interaction.
Our in vivo results showed that AFG given at 1 and 5
mg/kg/day was effective at prolonging survival. These data cor-
respond to those already reported for other experimental mod-
els of aspergillosis (26, 32).
Here, we found that the combination was not more effective
than the most active drug alone in all three survival experi-
ments.
In terms of kidney tissue burdens, we found that AFG given
at 5 mg/kg/day, but not at 1 mg/kg/day, reduced fungal burden
with respect to that in untreated controls. The combination
was not more active than AFG alone. Several published studies
have already explored the effects of echinocandins other than
FIG. 2. Survival of mice infected intravenously with the A. fumigatus F3 clinical isolate. In study 1, the animals were infected with 1.5  107
conidia/mouse and treated with AMB at 1 mg/kg/day, AFG at 1 mg/kg/day, and the respective combination regimen; in study 2, the mice were
infected with 3.5  105 conidia/mouse and treated with AMB at 1 mg/kg/day, AFG at 1 mg/kg/day, and the respective combination; in study 3, the
animals were infected with 3.2  106 A. fumigatus conidia/mouse and treated with AMB at 0.5 mg/kg/day, AFG at 5 mg/kg/day, and the
corresponding combination. The therapies were started 2 h postinfection (day 0) and continued through day 4 postinfection (five consecutive days).
There were from 9 to 16 mice in each group. Asterisks indicate groups with prolonged survival over controls (due to multiple comparisons, P values
of 0.016 were considered statistically significant).
TABLE 2. Fungal burden in tissues of A. fumigatus-infected mice measured by CFU and quantitative PCR assaysa
Challenge dose
(conidia/mouse)
Treatment
(drug, dose
mg/kg/day)
Brain burden Kidney burden
Mean log10
CFU/g of
tissue  SD
Mean log10
CE/g of
tissue  SD
Mean log10
CFU/g of
tissue  SD
Mean log10
CE/g of
tissue  SD
3.5  105 Control 3.17  0.44 4.49  0.35 5.12  0.26 7.85  0.57
AMB, 1 2.51  0.74 3.73  0.81 4.74  0.43 7.17  0.64
AFG, 1 3.02  0.83 4.50  1.09 4.95  0.27 7.42  0.59
AMB, 1  AFG, 1 3.06  0.60 4.78  0.47 4.89  0.44 7.78  0.53
3.2  106 Control 3.73  0.25 5.60  0.36 5.31  0.15 7.68  0.22
AMB, 0.5 3.82  0.22 5.88  0.71 4.96  0.32 7.36  0.34
AFG, 5 4.08  0.40 6.27  0.65 4.60  0.50* 6.61  0.66*
AMB, 0.5  AFG, 5 4.16  0.71 6.58  0.98 4.24  0.39* 6.50  0.62*
a The animals were infected with the A. fumigatus F3 isolate (3.5  105 conidia/mouse and 3.2  106 conidia/mouse in studies 2 and 3, respectively) and euthanized
3 days later. There were seven animals per group, and fungal burdens of brains and kidneys were determined by measuring CFU or conidial equivalents (CE) per gram
of tissue. Asterisks indicate treatment groups with reduced fungal burdens over the controls (due to multiple comparisons, P values of 0.016 were considered
statistically significant).
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AFG combined with various AMB formulations against As-
pergillus spp. Although two studies suggested that there were
beneficial effects from combined therapies (i.e., caspofungin
plus AMB and micafungin plus AMB) over the monotherapies
(11, 30), most studies showed that combinations did not en-
hance the effects of the most active single drug (8, 9, 13, 15,
18, 31).
We showed that neither single drugs nor combinations were
active in brain tissues. The lack of AFG efficacy in brains, but
not in kidneys, might be explained by its pharmacokinetics
features. Groll et al. (14) have studied the AFG tissue distri-
bution in healthy rabbits and reported an undetectable cere-
brospinal fluid concentration. Overall, our results showed that
the new echinocandin AFG has the potential to be used as a
therapeutic treatment against invasive aspergillosis. The com-
bination therapy of AFG with AMB did not improve the out-
comes analyzed in the present study, although antagonism was
not observed.
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